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Abstract
Background: Sphingolipids play important roles in cell structure and function as well as in the pathophysiology of
many diseases. Many of the intermediates of sphingolipid biosynthesis are highly bioactive and sometimes have
antagonistic activities, for example, ceramide promotes apoptosis whereas sphingosine-1-phosphate can inhibit
apoptosis and induce cell growth; therefore, quantification of the metabolites and modeling of the sphingolipid
network is imperative for an understanding of sphingolipid biology.
Results: In this direction, the LIPID MAPS Consortium is developing methods to quantitate the sphingolipid
metabolites in mammalian cells and is investigating their application to studies of the activation of the RAW264.7
macrophage cell by a chemically defined endotoxin, Kdo2-Lipid A. Herein, we describe a model for the C16-branch
of sphingolipid metabolism (i.e., for ceramides with palmitate as the N-acyl-linked fatty acid, which is selected
because it is a major subspecies for all categories of complex sphingolipids in RAW264.7 cells) integrating
lipidomics and transcriptomics data and using a two-step matrix-based approach to estimate the rate constants
from experimental data. The rate constants obtained from the first step are further refined using generalized
constrained nonlinear optimization. The resulting model fits the experimental data for all species. The robustness of
the model is validated through parametric sensitivity analysis.
Conclusions: A quantitative model of the sphigolipid pathway is developed by integrating metabolomics and
transcriptomics data with legacy knowledge. The model could be used to design experimental studies of how
genetic and pharmacological perturbations alter the flux through this important lipid biosynthetic pathway.
Background
Sphingolipids (SL) are categorized as lipids with a sphin-
goid base backbone [1] that is often derivatized with an
amide-linked fatty acid to make ceramides (Cer) and
more structurally complex SL with diverse biological
functions [2]. SL in essentially every subcategory, from
the lipid backbones [3] to complex SL [4], are highly
bioactive and play important roles in diseases [5,6];
hence, methods for “lipidomic” analysis of SL and SL
metabolism are important for an in-depth understanding
of these enigmatic compounds. In recent years, a num-
ber of large-scale experimental and bioinformatics pro-
jects have begun to address the complexity of the
lipidome. Examples include the Lipid Metabolites and
Pathways Strategy (LIPID MAPS) Consortium [7], The
Lipid Library [8], CYBERLIPID CENTER [9] and Lipid-
Bank [10]. In particular, LIPID MAPS has become a
comprehensive resource for information on classifica-
tion, structures and quantitative data on lipids and pro-
vides an opportunity for developing quantitative models
of lipid synthesis and metabolism thus facilitating a
mechanistic and systems-level understanding.
The de novo biosynthesis of SL begins with produc-
tion of the sphingoid base, which utilizes serine and pal-
mitoyl-coenzyme A (CoA) and various fatty acyl-CoAs
to make N-acylsphinganines (dihydroceramides, DHCer)
that are desaturated to Cer (N-acylsphingosines) and
incorporated into more complex SL such as ceramide 1-
phosphate (CerP), sphingomyelin (SM), glucosyl- and
galactosyl-ceramide (GlcCer and GalCer) and more
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synthesized by recycling of sphingosine from turnover of
SL such as SM [11,12]; furthermore, sphingosine and
sphinganine are phosphorylated to sphingosine 1-phos-
phate (S1P) and sphinganine 1-phosphate (DHSph1P)
which are intermediates of sphingoid base degradation
[13] and cell signaling molecules [14].
Due to the complexity of this pathway, and the paucity
of data for its many metabolites, there are only a few mod-
els of SL metabolism available in the literature [15-18].
The LIPID MAPS Consortium [7] has quantified the glo-
bal changes in lipid metabolites and genes in RAW 264.7
macrophage cells treated with Kdo2-Lipid A (KLA). KLA
is the active component of inflammatory lipopolysacchar-
ide which functions as a selective agonist of Toll-like
receptor 4 (TLR4) and mimics bacterial infection. The
measurements are carried out over a 24-hour time period
and the data is freely available via the LIPID MAPS web-
site [7]. The goal of the work presented here is to develop
a predictive kinetic model for SL metabolism using the
lipidomics and transcriptomics data from the LIPID
MAPS studies. This manuscript is organized as follows: we
first briefly discuss the experimental data preprocessing
and the methodology used for estimating the rate para-
meters, then we present the results of parameter estima-
tion, followed by discussion and conclusions.
Methods
Network simplification
A detailed metabolic reaction network was developed
using the information available in the literature and the
KEGG pathways database [19] (Figure 1). The C16-
branch of Cer biosynthesis (i.e., the Cer and DHCer
with palmitate as the N-acyl-linked fatty acid) was
selected for developing the model because this is a
major subspecies for all categories of complex SL in the
RAW264.7 cells. VANTED software was used to draw
the reaction network [20]. It is common in modeling
studies for the network to contain several unmeasured
nodes (e.g. metabolites and genes); in our pathway
(Figure 1), quantities are known for all of the metabo-
lites and genes except DHGalCer and GalCer (which are
present in such small amounts that they are below the
limit of detection until the cells are activated) and are
expressed as leaf-nodes (last metabolite in each branch)
in the network. One of the steps in our matrix-based
fast algorithm for parameter-estimation requires experi-
mental data on all metabolites except on the leaf-nodes/
metabolites in the network. A detailed procedure for
simplifying the network, if the network contains unmea-
sured components, is described in our previous work
[21]. The leaf-nodes were exempted from the model
described in this paper because the reactions leading to
the unmeasured leaf metabolites were combined with
the default degradation of their precursors.
Experimental data and preprocessing
The LIPID MAPS Consortium has measured all the
major lipids in mouse macrophage RAW 264.7 cells
grown in 10% serum and treated with KLA. All metabo-
lites were measured in pmol/μg-DNA units. The time-
courses of lipids and genes were measured under two
conditions: (a) normal condition designated as control
and (b) inflamed condition (stimulation by KLA). Time
series comprising of 8 data points at 0, 0.5, 1, 2, 4, 8, 12
and 24 hr were measured with three biological replicates
consisting of three technical replicates each. The three
technical replicate experiments were performed on the
same day with a single batch of cells. In addition, each
time course was repeated three times on different days
with different batches of cells (biological replicates). For
kinetic modeling purposes, outlier points were detected
by a t-test and were excluded at each time-point. The
resulting data from all the replicates were averaged at
each time-point. Data was processed for all metabolites
under the treatment with KLA and control conditions.
Serine palmitoyltransferase activity in vitro was deter-
mined using the assay conditions described previously
[22] but with [U-
13C]palmitoyl-CoA as the labeled sub-
strate. After extraction of the products, the amounts of
[
13C]3-ketosphinganine were determined by liquid chro-
matography, electrospray-ionization tandem mass spec-
trometry [23]. The assay was conducted using 100 μgo f
protein obtained by sonication of RAW264.7 cells in the
buffer used for the assay.
Development of a kinetic model and parameter
estimation
We have developed a kinetic model of the SL metabo-
lism. The procedure is similar to the one described in
our previous work [21,24], but it is presented here
through an example of reactions from the SL network for
completeness. The reaction rates were described by linear
or law of mass action kinetics with the assumption that
for enzymatic reactions, the substrate concentrations are
much smaller as compared to the corresponding Michae-
lis constant, Km. For example, the following types of reac-
tion schemes and rate expressions were used:
Reaction Rateexpressions
AB k A
AB A BkA B
Enz A B k



*[ ]
.* [ ] * [ ]
[] * [ E Enz A ]*[ ]
The enzymes involved in SL metabolism can be regu-
lated at multiple levels from mRNA expression to
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involved in the pathway is available from microarray
experiments (Additional file 1 Table S1). However, the
corresponding proteomics data is not available. Hence,
in our modeling approach, we have captured the effect
of temporal changes in transcription and protein levels
by utilizing the microarray data with a three hour time
delay as an input to the model. This assumes that the
corresponding protein profile is similar to the mRNA
time-course with the three hour delay, i.e., p(t) = g(t-3)
where p(t) and g(t) denote the level of protein and
gene-mRNA, respectively, at time t which is in hrs. A
three hour time-delay was chosen based on the general
consensus on delay in the protein synthesis from mRNA
Figure 1 Kdo2-Lipid A (KLA) stimulated sphingolipid metabolism pathway. The numbers above (or near) the arrows are reaction numbers
(Table 1). The default degradation reactions are not labeled. Metabolites and enzymes are represented as rectangular boxes with round corner
and rectangular boxes, respectively. The measured and unmeasured metabolites that are and are not present in detectable amounts are
differentiated by thick and thin borders, respectively. For full name of metabolites, see the list of abbreviations, presented at the end of the
manuscript.
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enzymes Sphk1 and Sphk2 catalyze the conversion of
DHSph into DHSph1P (Figure 1). This effect was func-
tionally captured through the reactions:
[] Sphk1 DHSph1P For theactivity of Sphk
f DHSph
k 4 1  
[] Sphk2 DHSph1P For theactivity of Sphk
f DHSph
k 5 2  
The effective rate of DHSph1P production was written
as (kf4×[Sphk1] + kf5× [Sphk2])×[DHSph]. The flux
expressions obtained from this scheme were linear in
rate parameters and nonlinear in metabolite concentra-
tions. The matrix-based approach to estimate the rate
constants is described below in terms of the reaction
numbers labeled in Figure 1 and listed in Table 1. Eq. 1
describes the rate of change of [DHSph1P] and [C16
DHGlcCer].
d[DHSph1P]
dt
k [DHSph][Sphk1] k [DHSph][Sphk2]
 k[ D H S p
f4 f5
f6

 h h1P]
d[C  DHGlcCer]
dt
k [C  DHCer][Ugcg] k [C  DHGlcC 16
f7 16 f8 16  e er]
(1)
where the rate constants ki (i = f4, f5, f6, f7, f8) are as
defined in Table 1.
If the metabolite concentrations were known and the
rate parameters were unknown, then the ordinary
Table 1 The estimated values of the rate parameters in the model of sphingolipid metabolism
No. Reactions Parameter
Names
Values
1 DHSph + CoA16 + CerS6 ® C16 DHCer kf1 1.30E+01 ± 1.01E-02
2 DHSph + CoA16 ® C16 DHCer kf2 5.62E-02 ± 1.30E-02
3C 16 DHCer ® kf3 1.11E-03 ± 3.20E-03
4 DHSph + Sphk1 ® DHSph1P kf4 1.49E-04 ± 1.11E-03
5 DHSph + Sphk2 ® DHSph1P kf5 1.61E-02 ± 8.38E-04
6 DHSph1P ® kf6 5.28E-01 ± 1.83E-02
7C 16 DHCer + Ugcg ® C16 DHGlcCer kf7 1.81E-02 ± 2.71E-03
8C 16 DHGlcCer ® kf8 2.99E-01 ± 3.25E-02
9C 16 DHCer + Sms1 + C16 GPCho ¬® kf9 1.15E-01 ± 6.85E-03
C16 DHSM + Sms1 + C16 DG kb9 1.7176 ± 5.47E-03
10 C16 DHCer + Sms2 + C16 GPCho ¬® kf10 3.88E-01 ± 1.02E-02
C16 DHSM + Sms2 + C16 DG kb10 8.63E-01 ± 1.23E-02
11 C16 DHSM + Smpd1 ® C16 DHCer kf11 1.07E-01 ± 5.62E-03
12 C16 DHSM ® kf12 2.49E-02 ± 3.01E-03
13 C16 DHCer + Cerk ® C16 DHCerP kf13 5.00E-05 ± 7.20E-06
14 C16 DHCerP ® kf14 8.25E-02 ± 6.57E-03
15 C16 DHCer + Degs1 ® C16 Cer kf15 9.07E-03 ± 9.56E-03
16 C16 DHCer ® C16 Cer kf16 8.03E-01 ± 1.39E-02
17 C16 Cer + Cerk ® C16 CerP kf17 1.29E-04 ± 7.64E-06
18 C16 CerP ® kf18 1.12E-01 ± 4.05E-03
19 C16 Cer + Sms1 + C16 GPCho ¬® kf19 6.50E-02 ± 3.13E-02
C16 SM + Sms1 + C16 DG kb19 4.72E-02 ± 8.67E-03
20 C16 Cer + Sms2 + C16 GPCho ¬® kf20 4.48E-01 ± 2.50E-02
C16 SM + Sms2 + C16 DG kb20 1.3343 ± 2.52E-02
21 C16 SM + Smpd1 ® C16 Cer kf21 1.91E-05 ± 1.98E-02
22 C16 SM ® kf22 9.79E-03 ± 1.28E-03
23 C16 Cer ® kf23 0.00E+00 ± 2.55E-03
24 C16 Cer + Ugcg ® C16 GlcCer kf24 2.39E-02 ± 3.05E-03
25 C16 GlcCer ® kf25 4.58E-03 ± 3.43E-03
Microarray data was used for protein concentration.
X ® means default degradation of the metabolite X.
Unit of first order reaction is 1/hr.
Unit of second order reaction is 1/hr when it involves protein as a modifier as we have used fold change data with respect to control for these variables.
Unit of third order reaction is μg DNA/(pmol * hr) when it involves protein as a modifier.
Unit of third order reaction is μg DNA/(Ratio Int * hr) when it involves DG and protein as modifiers.
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Page 4 of 12differential equations (ODEs) can be rearranged in a
matrix format as shown in Eq. 2.
d[DHSph1P]
dt
d[C DHGlcCer]
dt
[DHSph][Sphk1]
[D
16













0
H HSph][Sphk2]
[DHSph1P]
[C DHCer][Ugcg]
[C DHGlcCer]
16
16
0
0
0
0



 
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
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






T k
k
k
k
k
f4
f5
f
f
f
6
7
8
YX b *
(2)
The coefficients in the matrix X are linear/nonlinear
functions of metabolite and gene concentrations. All the
equations used in the simulation are listed in Appendix
A. X is completely defined. The left hand side of the
equations (matrix Y) was computed using discretization
and the experimental data (Eq. 3).
dx
dt
xx
tt tt k
tt tt
kk
kk






1
1
(3)
Eq. 2 contains known matrices X and Y, and the only
unknown in this equation is the rate-constant vector b.
The constrained least-squares approach (Matlab
® [26]
function lsqlin) was used to solve b. lsqlin optimized the
solution with objective function (Eq. 4) with additional
constraints that all parameter values have to be positive.
min
exp
YX b Y X b 
2 where and are: and  
dy
dt
dy
dt pred
(4)
The estimated values of the parameters were further
refined by using generalized constrained nonlinear opti-
mization (Matlab
® function fmincon) where the objec-
tive (Eq. 5) was to minimize the weighted fit-error
between the experimental and predicted metabolite con-
centrations. The algorithm of fmincon does not require
a matrix form. Thus, numerical integration was used (e.
g. Matlab
® function ode23)t os i m u l a t et h es y s t e mt o
circumvent the discretization error. The combined use
of lsqlin and fmincon made the overall process computa-
tionally efficient. The objective function for use with
fmincon was:
min ( ( , ))
:
,
,, e x p ,,
KX
ij ijp r e d
j
nt
i
nsp
yy K X
K
0
0
2
1 1









   
 p prameters (rate constants)
: Initial conditions (species X0    concentrations)
(5)
where, nt is the number of time-points and nsp is the
number of species.
The initial concentrations of the metabolites were also
optimized in a narrow range around the experimental
values. When data on more than one condition was
available, then all the data was used to compute the fit-
error by simulating the model several times individually
and minimizing the objective function collectively.
Estimation of uncertainty in the optimized parameters
The variation among the different technical and biologi-
cal replicates of lipid and gene data should be accounted
for in the estimated values of the parameters. Hence, an
uncertainty analysis was performed on the parameters.
Their standard error of mean (SEM) was computed as
follows:
1. Compute the SEM in the lipid and gene data at
each time point (Additional file 1 Table S1b).
2. Create a candidate data set for parameter estima-
tion by generating nsp x m random matrix utilizing
the normal distribution, scale it with the correspond-
ing SEM and add the scaled-value matrix to the
mean-value data on lipids and genes (Additional file
1 Table S1a).
3. Estimate the parameters using the candidate data
set thus producing a one parameter-value set.
4. Repeat steps 2-3 k times to generate k parameter-
value sets (k = 10 in our simulation).
5. Compute the SEM for each parameter across the
k sets.
Results
Fit to experimental data
ODEs were generated for all metabolites in the network
and effective rate constants were estimated for the sim-
plified SL reaction network using the approach
described in the “Methods” section. Table 1 lists the
reactions and the corresponding estimated reaction-rate
parameters included in the model. Lipid metabolism
and signaling are complex processes and the mechan-
isms involved are only partially known. KLA treatment
generated increases in most sphingolipids in RAW cells.
The increase in sphinganine (DHSph), which doubled in
4 hours, followed by increases in downstream metabo-
lites, including N-acyl-sphinganines (dihydroceramides,
DHCer) after a lag of approximately 2 to 4 hours
indicted the induction of de novo sphingolipid biosynth-
esis. To account the effect of KLA signaling, the time-
courses of the concentrations of DHSph, CoA16, C16
DG, C16 GPCho and microarray data were used as input
to the network (Additional file 1 Figure S1, Table S1).
Linear interpolations of these time-courses were used in
the integration. The decline in SL control experiment
data suggested that the control experiments were not at
steady state [7]. The assumption of steady-state was cir-
cumvented by including (fitting) data obtained in two
experimental scenarios, namely, the treatment with KLA
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meter-estimation. The microarray data was used to
represent the corresponding protein concentration with
3 hr time delay. For microarray data, fold change with
respect to the control was used in the simulation corre-
sponding to the treatment experiment (Additional file 1
Table S1). A fold-value of 1 was used in the simulation
corresponding to the control experiment. CerS5 and
Degs2 did not show significant change with respect to
the control in microarray data, thus the corresponding
reactions (reaction 2 and 14) were written without these
enzymes. The omission of these enzymes indicated their
constant activity in these reactions. The simplified model
is a reliable predictive model as evidenced by the good fit
to experimental data for most metabolites (Figure 2). For
C16 DHCer (top-left panel), the fit is good up to 8 hrs
after which it deteriorates. One possible reason for this
deterioration in the fit is the discrepancy between mRNA
and protein levels for the enzymes CerS5/6.
There were two problems in the optimization of para-
meters: (1) the wide range of metabolite concentrations,
and (2) irregular time intervals (longer intervals at later
times). The concentration of metabolites varied between
0.01 pmol/μgD N A( f o rC 16 DHCerP) and 700 pmol/μg
DNA (for C16 SM). Due to the orders of magnitude dif-
ference in the metabolite concentrations, the fits were
biased towards metabolites with high concentration and
resulted in a poor fit for the metabolites with lower con-
centrations. To resolve this issue, the experimental values
and predicted values for each metabolite were scaled/
normalized by its maximum experimental value. Then,
the sum of squares of the normalized fit-error on all
metabolites was minimized. This scaling, essentially, nor-
malized the maximum experimental concentrations to 1
for all metabolites and resulted in approximately equal
weight for all metabolites. Further, the data measured at
irregular time intervals (12 hr difference in last two mea-
surements) also created a problem in optimization and
Figure 2 Simulation results of kinetic modeling of sphingolipids network: Fit of the predicted response (control and treatment with
KLA) to the corresponding experimental data. In the legend, ‘Ctrl’ refers to control and ‘Trt’ refers to KLA treatment of RAW 264.7 cells. The
error-bars shown on the experimental data are standard-error of mean.
Gupta et al. BMC Systems Biology 2011, 5:26
http://www.biomedcentral.com/1752-0509/5/26
Page 6 of 12led to relatively poor fit at later time points. From para-
meter-estimation view-point, the measurements should
be made at equal intervals so that equal weight is
assigned to the entire time-course. To account for this,
the point-wise-error was scaled by the 1/4 power of the
length of the corresponding time-interval, resulting in a
higher weight for later time points. Consequently, the
quality of fit for the later time-points was improved. For
most time points, the difference between the predicted
and experimental data was within the standard-error of
mean (Figure 2). The good fit was obtained for all meta-
bolites under both treatment and control conditions.
Parametric sensitivity and time-scale analysis
Parametric sensitivity analysis: Parametric sensitivity analy-
sis was performed by varying all parameters (one at a time)
by two-fold up and down from its original (optimized)
value. The sensitivity of each metabolite was studied by
plotting the fold-change at its maximum concentration as
compared to the maximum concentration corresponding to
the original value of the parameter vs. the ratio-change in
the value of the perturbed parameter (Figure 3). The
numerical values of the sensitivity, i.e. the slope of the plots
at the optimized value of the parameter, are listed in Addi-
tional file 1 Table S2. For each parameter and each meta-
bolite, monotonic increase, decrease or no change was
observed depending upon the respective location of the
parameter and the metabolite chosen in the network. For
example, an increase in the parameter kf16 (C16 DHCer ®
C16 Cer) (Figure 3) produced a decrease in all upstream
metabolites except DHSph1P (Sphinganine-1P). An
increase is observed for Cer (Figure 3 sensitivity ~ 0.25)
and its downstream products such as Cer-1P, GlcCer, Gal-
Cer and SM. This is meaningful mechanistically because
the increase in kf16 increases the flux of the reaction C16
DHCer ® C16 Cer. If the level of C16 DHCer were not to
change much, then one would expect almost proportional
increase in C16 Cer (sensitivity ~ 1). However, this is not
Figure 3 Simulation results of parametric sensitivity analysis for the parameter kf16 (C16 DHCer ® C16 Cer). X-axis: ratio of perturbed
value of the parameter to the original (optimized) value of the parameter; Y-axis: fold-change in the maximum-value of state variables
(metabolites).
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~ -0.64). This results in a net sensitivity value of less than
1. Similarly, an increase in kf16 results in decreased
DHCer-1P, DHGlcCer, and DHSM levels. These metabo-
lites are products of DHCer and hence the sensitivities are
consistent with the structure of the biochemical reaction
network (Figure 1). Small to moderate sensitivities (Addi-
tional file 1 Table S2) suggest that the biochemical system
is robust with respect to parametric perturbations.
Uncertainty analysis on the parameters: The SEM of
the parameters is calculated as described in the Methods
section and the results are reported in Table 1. Overall,
the parameters are well-behaved and the parameter-esti-
mation procedure is reliable because the fractional SEM
for the lipid and gene data and the fractional SEM for
most of the parameters are of the same order (20-30%).
Time-scale analysis: Time-scale is an important intrin-
sic property of dynamical biological systems. While the
time-scale of metabolites, at which they evolve, can be
gleaned by analyzing several time-courses under differ-
ent conditions, a more systemic picture can be obtained
through eigenvalue and eigenvector analysis of the Jaco-
bian matrix of ordinary differential equations at the
steady-state conditions. In our computations, the steady-
state was identified by simulating the system corre-
sponding to the control condition (no stimulus) for a
long time (t = 1000 hr). The Jacobian matrix was com-
puted through numerical differentiation of the expres-
sions on the right hand sides of the ODEs with respect
to the state variables. The eigenvalues were split into
three broad ranges. For each eigenvalue, the metabolites
with substantial contribution to the corresponding
eigenvector were identified. Depending upon the eigen-
values and metabolites significantly contributing to the
corresponding eigenvectors, these metabolites have been
divided into three categories as listed in Table 2. When
a metabolite contributed significantly in two eigenvec-
tors spanning in two different eigen value ranges, the
metabolite was assigned to the smaller eigen value
because the fast manifold only determines its initial
transients and the slow manifold governs the later
response leading to steady state. A comparison of Table
2 and Figure 2 shows that the time scale of the metabo-
lite is dependent on its location (whether it is leaf node
metabolite or intermediate metabolite) and its concen-
tration. The medium time-scale metabolites (column 2
in Table 2) are the leaf node metabolites having low
concentration (~ 0.01-1 pmole/μg of DNA); the slow
time-scale metabolites (column 3 in Table 2) are the
leaf node metabolite with high concentration (~ 10
2-10
3
pmole/μg of DNA). DHCer and Cer have fast time-scale
because of their intermediate location in the network,
moderate concentration (~10 pmole/μgo fD N A )a n d
high flux through these nodes in the production of SM.
Discussion
This study has used the large data sets from mass spec-
trometric measurements of the SL and the microarray
data of the mRNAs of RAW264.7 cells generated by the
LIPID MAPS Consortium to evaluate a model for SL
metabolism.
Importance of including the transcriptomics data and the
data on fatty acyl-CoA
In this study, we have included the microarray data for
the lipid-related genes using a time-delay of three-hours
to account for the time for mRNA translation and pro-
tein translocation. The use of mRNA data for kinetic
modeling was motivated by good correlations between
specific genes and its metabolic products in the sphingo-
lipid pathway [27]. In general, protein levels follow the
qualitative profile of mRNA with appropriate time-
delays. However, we note the potential caveat that the
protein levels for some proteins may not be even quali-
tatively similar to the transcriptional levels of their
genes. The discrepancy of mismatch between the mRNA
and protein profiles can arise due to several factors such
as dependence of mRNA translation on ribosome bind-
ing site (RBS) sequences, post translational modification
of the protein, protein translocation and its stability.
This may introduce errors in the estimated values of the
kinetic parameters.
To delineate the importance of the transcriptional
data, we first developed the mathematical model without
using the gene/protein data. The rate parameters were
estimated using the lipidomics data alone. We visualized
the fit to experimental data (equivalent of the plots
shown in Figure 2; data not shown). A reasonable fit
was obtained for all metabolites except C16-DHCer. To
resolve disagreement in the shape of DHCer, we identi-
fied the reactions in which these lipids were consumed
or produced. We also analyzed the time-course of the
mRNA levels for the genes related to these reactions.
Most of the genes exhibited differential regulation at
later time points (i.e., the ratio of data with KLA treat-
ment to control being significantly different from 1).
Among several differentially regulated genes, the promi-
nent were CerS6 (reaction 1), Smpd1 (reactions 9 and
Table 2 Results of eigenvalue based time-scale analysis
of the metabolites
Fast (~1 hr) Medium (~10 hr) Slow (~100 hr)
C16 DHCer DHSph1P C16 SM
C16 Cer C16 DHGlcCer C16 GlcCer
C16 DHSM
C16 DHCerP
C16 CerP
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Page 8 of 1217), Degs1 (reaction 13) and Ugcg (reaction 20). The
up-regulation and involvement of CerS6 in the produc-
tion of DHCer suggested that the gene data must be
included in the network to capture the DHCer
dynamics. After adding the gene data with delay, we
observed substantial improvement in the fit to the
experimental data for DHCer (Figure 2).
The profile of palmitoyl-CoA16 also increases monoto-
nically during 0-24 hrs (Additional file 1 Figure S1). Even
though [DHSph] increases till 4 hr and comes back to
control level at 24 hr, the influx to DHCer is maintained
throughout 0-24 hr because of increase in palmitoyl-CoA
and CerS6 at later time points. Due to this reason,
DHCer shows a monotonically increasing profile during
0-24 hr. Thus, the profiles of CerS6 and palmitoyl-CoA
are important to obtain a good fit on DHCer.
Rate parameters for the enzymes
We compared the combined rate constant for the
enzymes CerS5/CerS6 (pmol/hr/μg-DNA) with an esti-
mation of the maximum flux through the de novo bio-
synthetic pathway based on the activity of serine
palmitoyltransferase assayed in vitro with optimal con-
centrations of substrates, which was 30 + 1 pmole/min/
mg protein for control (unstimulated) RAW264.7 cells.
To convert the estimated values to the same units, we
used estimations (by measurement) for the relationships
between DNA, cell number and protein amount of ~3 μg
DNA/10
6 RAW264.7 cells, and 10
6 cells have ~0.25 mg
protein. Thus, the computed value for C16-SL biosynth-
esis by CerS5/CerS6 is ~1 pmol/min/mg protein, which
is about one order of magnitude lower than the theoreti-
cal maximum rate of sphinganine production by the
cells. This might mean that the calculated value is low
due to inaccuracies in some of the modeling approxima-
tions, including the use of linear kinetics instead of
Michaelis-Menten kinetics; however, the differences
might be real because serine palmitoyltransferase has
usually not been found to be operating at Vmax because
its substrates are not saturating [28,29] and other CerS
also contribute to the utilization of the sphinganine that
is produced de novo. In addition, sphinganine and sphin-
ganine 1-phosphate are elevated to some extent in
RAW264.7 cells, which implies that CerSs are not trap-
ping all of the sphinganine that is made.
Similarity in the rate parameters for same gene/enzyme
involved in different reactions
Structurally, DHCer and Cer differ by one double bond
(Figure 4). However, both are converted to their corre-
sponding derivatives by four genes, namely Ugcg, Cerk
and Sms1/2 (Figure 1). To check the effects of this double
bond on the rate parameter, we compared the rate para-
meters for the above genes/enzymes in their reactions.
The rate parameter for SMS2 (kf10 and kf20) and Ugcg (kf7
and kf24) was found approximately similar for the both
reactions involving DHCer and Cer. For Sms1 and Cerk,
the rate parameters for the two reactions differed by a fac-
tor of 2 (Table 1). To further test whether we can find the
common rate constants for these enzymes in their reac-
tions, we carried out the optimization using same rate
constant for these enzymes in their reactions. We were
able to get reasonably good fit for all of the metabolites
(Figure 5). In the modified optimization, the values
obtained for these rate-parameters were between the cor-
responding values for the two reactions obtained in the
original optimization (Additional file 1 Table S3). This
result suggests that the affinities of these enzymes are
similar for both the substrates Cer and DHCer.
Consideration of different chain-lengths
C16 sphingolipids are used in this model because (1)
these are present in higher amounts than the SL of lar-
ger chain-lengths, and (2) they showed significant differ-
ences between the treatment and control experiments in
response to KLA. We can extend our model to include
the metabolites with higher chain-lengths (e.g. C18,C 20,
C22 and C24) .T h er e a c t i o n si nt h ee x i s t i n gm o d e l( C 16-
based) will serve as a template that can be instantiated
for higher chain-lengths. To estimate the rate para-
meters for the entire model, the parameters for the C16-
based model can provide bounds for the rate parameters
in the overall model for the similar types of reactions.
For example, the rate constants for the reactions Cn
DHCer ® Cn DHGlcCer (where n = 18, 20, 22 and 24),
can be constrained with a factor of 0.5 to 2 of the rate
constant for the reaction C16 DHCer ® C16 DHGlcCer
in the model developed here.
Use of the model for in-silico perturbation experiments
T h em o d e lc a nb eu s e dt op e r f o r mk n o c k d o w n( K D )o r
other perturbation experiments in-silico. Such computa-
tional studies provide useful insights into the behavior of
the system which can add in designing the actual pertur-
bation experiments. These simulations can assist in finding
Figure 4 Chemical structure of (a) C16 Cer and (b) C16 DHCer.
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Page 9 of 12the propagation of the effects of KD in the network and
lead to a better design of experiments (e.g. when the mea-
surements should be made). Simulation can also suggest
whether a high level of KD is needed such that the differ-
ences between the KD and control scenarios would be sta-
tistically significant. The data generated from new
perturbation experiments can be used to further refine the
model. For the enzymes, the KD perturbations can be
simulated by decreasing the corresponding rate parameter
because amount of the (active) enzyme directly affects the
rate parameters. The KD perturbation simulation results
will be similar to the sensitivity analysis results on the cor-
responding rate parameter. For example, the effect of 50%
KD of the enzyme for the reaction 16 (Figure 1 Degs2),
can be predicted from the simulation for sensitivity analy-
sis in which the value of the parameter kf16 is reduced by
50% (Figure 3).
The case of knockdown of Cerk (cermide kinase) is
also interesting due to its direct effect on Ceramide-1-
phosphate (CerP) which inhibits apoptosis and induces
cell growth [30]. The result of sensitivity analysis for the
corresponding rate parameter, kf17 (C16 Cer + Cerk ®
C16 CerP), is shown in Additional file 1 Figure S2.
Decrease in kf17 results in a corresponding decrease in
the CerP level. These changes have also been observed
in recent experiments validating our parametric sensitiv-
ity analysis and the predictive ability of the model [31].
CerP has also been implicated in regulating the homeos-
tasis of calcium [32] thereby affecting the activity of sev-
eral signaling pathways. CerP and Cerk mediate the
effect of cytokines to activate cytosolic phospholipase
A2 (cPLA2) and cyclooxygenase 2 (COX-2), resulting in
increased production of prostaglandin E2 (PGE2), a
mediator of inflammation [33]. Hence, it has been
Figure 5 Simulation results of kinetic modeling of sphingolipids network where parameters for CerK, Ugcg and SMS1/2 are same for
the reactions involving Cer and DHCer: Fit of the predicted response (control and treatment with KLA) to the corresponding
experimental data. In the legend, ‘Ctrl’ refers to control and ‘Trt’ refers to KLA treatment of RAW 264.7 cells. The error-bars shown on the
experimental data are standard-error of mean.
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Page 10 of 12hypothesized that Cerk could be a potential target for
anti-inflammatory drugs [34,35].
Conclusion
Use of systems biology approaches is becoming more
common in the study of lipids to elucidate their func-
tions and roles in human health and diseases such as
arthritis and cancer. Systems biology has already been
recognized as an indispensable tool in pathway-based
drug discovery. Here we have applied a matrix-based
approach to develop a dynamic model of SL metabo-
lism by integrating legacy information on the lipid
pathways with novel experimental data. The metabolic
pathway was reconstructed using information from the
KEGG database and the existing literature. Based upon
the network map reconstructed, we have developed an
ordinary differential equations-based mathematical
model. Parameter-estimation used a two-step
approach. In the first step, a matrix-based approach
provided an initial guess. The parameter-values were
further refined in the second step. The resulting model
fitted the experimental data well for all species and
demonstrated that the integrated metabolic and signal-
ing network and the experimental data are consistent
with each other. The robustness of the model para-
meters was also validated through sensitivity analysis.
Though we have used this two-step approach pre-
viously and applied it to eicosanoid lipid pathway, the
major distinction lies in its application to the SL meta-
bolic pathway and the integration of transcriptomic
data with the metabolomic data along with legacy
knowledge to develop the kinetic model. Previous com-
putational models of sphingolipid metabolism were for
non-mammalian systems in which only a few metabo-
lites were measured as compared to the total number
of metabolites in the reaction network. In comparison,
our model is based on a large amount of experimental
time-course data where the concentrations of most
metabolites and mRNA levels of genes in the network
are measured. This provides a more context-specific
model for RAW cells in particular and for mammalian
cell systems in general.
Appendix A
The flux expressions for the reactions shown in Figure 1
are as follows:
v1 =k f1[DHSph][CoA16][CerS6]
v2 =k f2[DHSph][CoA16]
v3 =k f3[C16 DHCer]
v4 =k f4[DHSph][Sphk1]
v5 =k f5[DHSph][Sphk2]
v6 =k f6[DHSph1P]
v7 =k f7[C16 DHCer][Ugcg]
v8 =k f8[C16 DHGlcCer]
v9 =k f9[C16 DHCer][Sms1][C16 GPCho] - kb9[C16
DHSM][Sms1][C16 DG]
v10 =k f10[C16 DHCer][Sms2][C16 GPCho] - kb10[C16
DHSM][Sms2][C16 DG]
v11 =k f11[C16 DHSM][Smpd1]
v12 =k f12[C16 DHSM]
v13 =k f13[C16 DHCer][Cerk]
v14 =k f14[C16 DHCerP]
v15 =k f15[C16 DHCer][Degs1]
v16 =k f16[C16 DHCer]
v17 =k f17[C16 Cer][Cerk]
v18 =k f18[C16 CerP]
v19 =k f19[C16 Cer][Sms1][C16 GPCho] - kb19[C16 SM]
[Sms1][C16 DG]
v20 =k f20[C16 Cer][Sms2][C16 GPCho] - kb20[C16 SM]
[Sms2][C16 DG]
v21 =k f21[C16 SM][Smpd1]
v22 =k f22[C16 SM]
v23 =k f23[C16 Cer]
v24 =k f24[C16 Cer][Ugcg]
v25 =k f25[C16 GlcCer]
T h ed i f f e r e n t i a le q u a t i o n sd e s c r i b i n gt h er a t eo f
change of metabolite concentrations are:
d[C16 DHCer]/dt = v1 +v 2 -v 3 -v 7 -v 9 -v 10 +v 11 -
v13 -v 15 -v 16
d[DHSph1P]/dt = v4 +v 5 -v 6
d[C16 DHGlcCer]/dt = v7 -v 8
d[C16 DHSM]/dt = v9 +v 10 -v 11 -v 12
d[C16 DHCerP]/dt = v13 -v 14
d[C16 Cer]/dt = v15 +v 16 -v 17 -v 19 -v 20 +v 21 -v 23 -v 24
d[C16 CerP]/dt = v17 -v 18
d[C16 SM]/dt = v19 +v 20 -v 21 -v 22
d[C16 GlcCer]/dt = v24 -v 25
Additional material
Additional file 1: Supporting Material. This file is in PDF format and
contains additional Figures S1-S2 and additional Tables S1-S3.
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phosphodiesterase 1, acid lysosomal; Sphk1: sphingosine kinase 1; Sphk2:
sphingosine kinase 2; Sms1: sphingomyelin synthase 1; Sms2: sphingomyelin
synthase 2; Ugcg: UDP-glucose ceramide glucosyltransferase; C16 Cer: N-
(hexadecanoyl)- sphing-4-enine (C16 Ceramide); C16 CerP: N-(hexadecanoyl)-
sphing-4-enine-1-phosphate (C16 Ceramide-1-phosphate); C16 GlcCer: N-
(hexadecanoyl)-1-β- sphing-4-enine (C16 Glucosylceramide); C16 SM: N-
(hexadecanoyl)- sphing-4-enine -1-phosphocholine (C16 Sphingomyelin); C16
DHCer: N-(hexadecanoyl)-sphinganine (C16 Dihydroceramide); C16 DHCerP:
N-(hexadecanoyl)-sphinganine-1-phosphate; C16 DHGlcCer: N-
(hexadecanoyl)-1-β-glucosyl-sphinganine; C16 DHSM: N-(hexadecanoyl)-
sphinganine-1-phosphocholine; DHSph: Sphinganine; DHSph1P:
Sphinganine-1-phosphate; DHGalCer: Dihydro Galactosylceramide; GalCer:
Galactosylceramide;
Gupta et al. BMC Systems Biology 2011, 5:26
http://www.biomedcentral.com/1752-0509/5/26
Page 11 of 12Acknowledgements
We would like to acknowledge the assistance of Eoin Fahy for preparing the
network map of sphingolipid metabolism, and Elaine Wang, Kristin Jones,
Samuel Kelly, Rebecca Shaner and Jeremy Allegood for the analysis of the
sphingolipids by mass spectrometry. This research was supported by NIH
Collaborative Grant U54 GM69338-04 LIPID MAPS (S.S.) and NIDDK Grant
P01-DK074868 (S.S., and C.K.G.).
Author details
1Department of Bioengineering, University of California, San Diego, 9500
Gilman Dr., La Jolla CA 92093, USA.
2School of Biology & Petit Institute for
Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA
30332-0230, USA.
3Department of Cellular and Molecular Medicine, University
of California, San Diego, 9500 Gilman Dr., La Jolla CA 92093, USA.
4Department of Chemistry & Biochemistry, San Diego Supercomputer Center
and Graduate Program in Bioinformatics, University of California, San Diego,
9500 Gilman Dr., La Jolla CA 92093, USA.
Authors’ contributions
SG designed the simulations, wrote the computer program, analyzed the
experimental data and the simulation results and wrote the manuscript.
AHM assisted in refining the reaction network. MRM assisted in designing
some of the simulations, wrote part of the computer program and
contributed in writing the manuscript. AHM, CKG and SS assisted in revising
the manuscript. Sphingolipid and enzyme activity measurements were
carried out in the laboratory of AHM. Transcriptomics experiments were
carried out in the laboratory of CKG. SS supervised the modeling study. All
authors have read and approved the final manuscript.
Received: 18 August 2010 Accepted: 8 February 2011
Published: 8 February 2011
References
1. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill AH, Murphy RC,
Raetz CRH, Russell DW, Seyama Y, Shaw W, et al: Ac o m p r e h e n s i v e
classification system for lipids. Journal of lipid research 2005,
46(5):839-862.
2. Merrill AH, Wang MD, Park M, Sullards MC: (Glyco)sphingolipidology: an
amazing challenge and opportunity for systems biology. Trends Biochem
Sci 2007, 32(10):457-468.
3. Zheng W, Kollmeyer J, Symolon H, Momin A, Munter E, Wang E,
Kelly S, Allegood JC, Liu Y, Peng Q, et al: Ceramides and other
bioactive sphingolipid backbones in health and disease: lipidomic
analysis, metabolism and roles in membrane structure, dynamics,
signaling and autophagy. Biochim Biophys Acta 2006,
1758(12):1864-1884.
4. Lopez PH, Schnaar RL: Gangliosides in cell recognition and membrane
protein regulation. Curr Opin Struct Biol 2009, 19(5):549-557.
5. Zeidan YH, Hannun YA: Translational aspects of sphingolipid metabolism.
Trends Mol Med 2007, 13(8):327-336.
6. Wennekes T, van den Berg RJ, Boot RG, van der Marel GA, Overkleeft HS,
Aerts JM: Glycosphingolipids–nature, function, and pharmacological
modulation. Angew Chem Int Ed Engl 2009, 48(47):8848-8869.
7. Murphy RC, Fiedler J, Hevko J: Analysis of nonvolatile lipids by mass
spectrometry. Chem Rev 2001, 101(2):479-526.
8. KEGG BRITE database. [http://www.genome.jp/kegg/brite.html].
9. SphinGOMAP pathways. [http://sphingolab.biology.gatech.edu].
10. Gehlenborg N, O’Donoghue SI, Baliga NS, Goesmann A, Hibbs MA,
Kitano H, Kohlbacher O, Neuweger H, Schneider R, Tenenbaum D, et al:
Visualization of omics data for systems biology. Nat Methods 2010, 7(3
Suppl):S56-68.
11. Bartke N, Hannun YA: Bioactive sphingolipids: metabolism and function.
Journal of lipid research 2009, 50(Suppl):S91-96.
12. Kitatani K, Idkowiak-Baldys J, Hannun YA: The sphingolipid salvage
pathway in ceramide metabolism and signaling. Cell Signal 2008,
20(6):1010-1018.
13. Fyrst H, Saba JD: Sphingosine-1-phosphate lyase in development and
disease: sphingolipid metabolism takes flight. Biochim Biophys Acta 2008,
1781(9):448-458.
14. Maceyka M, Milstien S, Spiegel S: Sphingosine-1-phosphate: the Swiss
army knife of sphingolipid signaling. Journal of lipid research 2009,
50(Suppl):S272-276.
15. Henning PA, Merrill AH, Wang MD: Dynamic pathway modeling of
sphingolipid metabolism. Conf Proc IEEE Eng Med Biol Soc 2004,
4:2913-2916.
16. Alvarez-Vasquez F, Sims KJ, Cowart LA, Okamoto Y, Voit EO, Hannun YA:
Simulation and validation of modelled sphingolipid metabolism in
Saccharomyces cerevisiae. Nature 2005, 433(7024):425-430.
17. Henning P, Moffitt R, Allegood J, Wang E, Merrill A, Wang M:
Computationally predicting rate constants in pathway models. Conf Proc
IEEE Eng Med Biol Soc 2005, 5:5093-5096.
18. Garcia J, Shea J, Alvarez-Vasquez F, Qureshi A, Luberto C, Voit EO, Del
Poeta M: Mathematical modeling of pathogenicity of Cryptococcus
neoformans. Mol Syst Biol 2008, 4:183.
19. Kyoto Encyclopedia of Genes and Genomes (KEGG). [http://www.
genome.ad.jp/kegg/].
20. Junker BH, Klukas C, Schreiber F: VANTED: A system for advanced data
analysis and visualization in the context of biological networks. BMC
Bioinformatics 2006, 7.
21. Gupta S, Maurya MR, Stephens DL, Dennis EA, Subramaniam S: An
Integrated Model of Eicosanoid Metabolism and Signaling Based on
Lipidomics Flux Analysis. Biophysical Journal 2009, 96(11):4542-4551.
22. Merrill AH Jr: Characterization of serine palmitoyltransferase activity in
Chinese hamster ovary cells. Biochim Biophys Acta 1983, 754(3):284-291.
23. Sullards MC, Allegood JC, Kelly S, Wang E, Haynes CA, Park H, Chen Y,
Merrill AH Jr: Structure-specific, quantitative methods for analysis of
sphingolipids by liquid chromatography-tandem mass spectrometry:
“inside-out” sphingolipidomics. Methods Enzymol 2007, 432:83-115.
24. Maurya MR, Subramaniam S: A kinetic model for calcium dynamics in
RAW 264.7 cells: 1. Mechanisms, parameters, and subpopulational
variability. Biophys J 2007, 93(3):709-728.
25. Yoshikawa K, Kita Y, Kishimoto K, Shimizu T: Profiling of eicosanoid
production in the rat hippocampus during kainic acid-induced seizure:
dual phase regulation and differential involvement of COX-1 and COX-2.
The Journal of biological chemistry 2006, 281(21):14663-14669.
26. The Mathworks, Inc.© 1994 - 2010. [http://www.mathworks.com/].
27. Dennis EA, Deems RA, Harkewicz R, Quehenberger O, Brown HA, Milne SB,
Myers DS, Glass CK, Hardiman GT, Reichart D, et al: A Mouse Macrophage
Lipidome. J Biol Chem 2010, 285(51):39976-39985.
28. Messmer TO, Wang E, Stevens VL, Merrill AH Jr: Sphingolipid biosynthesis
by rat liver cells: effects of serine, fatty acids and lipoproteins. J Nutr
1989, 119(4):534-538.
29. Merrill AH, Wang E, Mullins RE: Kinetics of long-chain (sphingoid) base
biosynthesis in intact LM cells: effects of varying the extracellular
concentrations of serine and fatty acid precursors of this pathway.
Biochemistry 1988, 27(1):340-345.
30. Gomez-Munoz A: Ceramide 1-phosphate/ceramide, a switch between life
and death. Biochim Biophys Acta 2006, 1758(12):2049-2056.
31. Niwa S, Graf C, Bornancin F: Ceramide kinase deficiency impairs
microendothelial cell angiogenesis in vitro. Microvasc Res 2009,
77(3):389-393.
32. Hinkovska-Galcheva V, VanWay SM, Shanley TP, Kunkel RG: The role of
sphingosine-1-phosphate and ceramide-1-phosphate in calcium
homeostasis. Curr Opin Investig Drugs 2008, 9(11):1192-1205.
33. Pettus BJ, Kitatani K, Chalfant CE, Taha TA, Kawamori T, Bielawski J,
Obeid LM, Hannun YA: The coordination of prostaglandin E2 production
by sphingosine-1-phosphate and ceramide-1-phosphate. Mol Pharmacol
2005, 68(2):330-335.
34. Saxena S, Banerjee M, Shirumalla RK, Ray A: Ceramide kinase: a potential
anti-inflammatory target? Curr Opin Investig Drugs 2008, 9(5):455-462.
35. Lamour NF, Chalfant CE: Ceramide kinase and the ceramide-1-phosphate/
cPLA2alpha interaction as a therapeutic target. Curr Drug Targets 2008,
9(8):674-682.
doi:10.1186/1752-0509-5-26
Cite this article as: Gupta et al.: Integration of lipidomics and
transcriptomics data towards a systems biology model of sphingolipid
metabolism. BMC Systems Biology 2011 5:26.
Gupta et al. BMC Systems Biology 2011, 5:26
http://www.biomedcentral.com/1752-0509/5/26
Page 12 of 12